Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|January 7, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-02-03-2016
- Volume 12
- Issue 2
Charles River Laboratories Acquires WIL Research
Author(s)Pharmaceutical Technology Editors
Charles River Laboratories entered into a definitive agreement to acquire WIL Research.
Advertisement
On Jan. 7, 2016, Charles River Laboratories International announced that it has entered into a definitive agreement to acquire WIL Research for approximately $585 million in cash, subject to customary closing adjustments.
WIL Research is a provider of safety assessment and contract development and manufacturing (CDMO) services to biopharmaceutical, agricultural, and industrial chemical companies worldwide.
According to a press announcement from the company, the acquisition of WIL Research will assist the company in diversifying its science portfolio. This includes the addition of new specialty services in safety assessment, bioanalysis, and CDMO services.
The transaction is expected to close early in the second quarter of 2016, subject to regulatory approvals and customary closing conditions. Based on the anticipated timing of the close, the acquisition is expected to add $150 to $170 million to Charles River’s 2016 consolidated revenue, and $240 to $250 million to 2017 consolidated revenue.
Source:
Articles in this issue
over 10 years ago
Is Consolidation Good for Pharma?over 10 years ago
Parenteral Packagers Focus on Security and Supply-Chain Transparencyover 10 years ago
Hermes Pharma Adds Hot Melt Coating Capabilityover 10 years ago
Novasep Adds Small-Scale Manufacturing Capability to US Facilityover 10 years ago
Vetter Completes Development and IT Facilityover 10 years ago
Adents, Siemens Team on Serialization Solutionover 10 years ago
Onyx Scientific Announces Facility Expansionover 10 years ago
FDA’s CDER Previews 2016 Guidance AgendaAdvertisement
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Advertisement
Advertisement